Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
As biliary tract cancer (BTC) patients typically survive less than one year on standard-of-care chemotherapy, adapting prognostic biomarkers to guide their management remains challenging. Høgdall et al. measured 1590 serum IL-6, YKL-40, and CA19-9 samples before and during chemotherapy in 452 advanced BTC patients. While all markers provided variable prognostic information prior to treatment, longitudinal analysis of IL-6 was superior in predicting death during treatment. Blocking IL-6 signalling with tocilizumab (IL-6 receptor monoclonal antibody) significantly increased response to gemcitabine in a mouse model of human BTC. Thus, the IL-6 axis may be prognostically informative and therapeutically attractive in this rare patient demographic.
(Høgdall D et al. – Clin Cancer Res, 15 September 2020)
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.